Full Name
Dr. Àlex Rovira
Position/Title
Head Neuroradiology
Organization/Company
Hospital Vall d'Hebron
Speaker Bio
Dr Rovira is the Director of the Section of Neuroradiology at University Hospital Vall d’Hebron, and of the Neuroradiology Research Group at Vall d’Hebron Research Institute (VHIR), Barcelona (Spain).
He is currently chair of Referral Guidelines Subcommittee of the European Society of Radiology and of the ESNR Green Committee, and member of MAGNIMS (European Multicenter Collaborative Research Network on MRI in MS). He is on the editorial boards of Neurology and Canadian Association of Radiologist Journal.
He is Honorary Lecturer at University College of London, and served as associate Professor of Radiology and Neuroimmunology at the Autonomous University of Barcelona, and as Honorary Associated Professor at University College of London.
He also served as President of the European Society of Neuroradiology (2016-2018) and as President of the Spanish Society of Neuroradiology (2009-2015).
Dr Rovira has authored/co-authored more than 600 articles (Scopus; total citations 26.000; h-index: 88), 30 book chapters or monographs, and more than 500 invited conference presentations. He has been invited as Visiting Professor at the University of Toronto, McGill University (Montreal), Lysholm Department of Neuroradiology (UCL, London), Ottawa University, and University of North Carolina (Chapel Hill).
He is an honorary member of the European Society of Neuroradiology, the Bulgarian Society of Neuroradiology, the Paulista Society of Radiology, and of the Polish Society of Radiology.
Dr Rovira has made relevant contributions on the value of MRI as a biomarker in different neurological disorders, in particular in autoimmune central nervous system disorders.
The speaker discloses the following relationships:
• Receipt of financial payments from Bayer, Sanofi, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, Bristol-Myers, and Biogen.
• Service on advisory boards or bureaus for Novartis, Sanofi-Genzyme, Synthetic MR, TensorMedical, Roche, and Biogen, with payments received personally or on behalf of their institution.
• Recipient of funded grants for research projects PI19/00950 and PI22/01589 from the Fondo de Investigación en Salud at Instituto de Salud Carlos III, Spain.
• Service as Chief Medical Officer (CMO) and co-founder of TensorMedical.
He is currently chair of Referral Guidelines Subcommittee of the European Society of Radiology and of the ESNR Green Committee, and member of MAGNIMS (European Multicenter Collaborative Research Network on MRI in MS). He is on the editorial boards of Neurology and Canadian Association of Radiologist Journal.
He is Honorary Lecturer at University College of London, and served as associate Professor of Radiology and Neuroimmunology at the Autonomous University of Barcelona, and as Honorary Associated Professor at University College of London.
He also served as President of the European Society of Neuroradiology (2016-2018) and as President of the Spanish Society of Neuroradiology (2009-2015).
Dr Rovira has authored/co-authored more than 600 articles (Scopus; total citations 26.000; h-index: 88), 30 book chapters or monographs, and more than 500 invited conference presentations. He has been invited as Visiting Professor at the University of Toronto, McGill University (Montreal), Lysholm Department of Neuroradiology (UCL, London), Ottawa University, and University of North Carolina (Chapel Hill).
He is an honorary member of the European Society of Neuroradiology, the Bulgarian Society of Neuroradiology, the Paulista Society of Radiology, and of the Polish Society of Radiology.
Dr Rovira has made relevant contributions on the value of MRI as a biomarker in different neurological disorders, in particular in autoimmune central nervous system disorders.
The speaker discloses the following relationships:
• Receipt of financial payments from Bayer, Sanofi, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, Bristol-Myers, and Biogen.
• Service on advisory boards or bureaus for Novartis, Sanofi-Genzyme, Synthetic MR, TensorMedical, Roche, and Biogen, with payments received personally or on behalf of their institution.
• Recipient of funded grants for research projects PI19/00950 and PI22/01589 from the Fondo de Investigación en Salud at Instituto de Salud Carlos III, Spain.
• Service as Chief Medical Officer (CMO) and co-founder of TensorMedical.
Speaking At
